A blueberry-derived relative of resveratrol, absorbed far more efficiently. Lab and animal work shows broad promise for heart, metabolism, brain, and anti-cancer effects, and it reliably strengthens antioxidant defenses. Human evidence is thin and mixed: it lowered blood pressure but unexpectedly raised "bad" cholesterol when taken on its own. Mechanistically interesting but clinically unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | < 100 mg/dL (lower for high CV risk) | Detects the main documented risk: pterostilbene monotherapy can raise LDL |
| Total & HDL cholesterol, triglycerides | HDL > 50 mg/dL; triglycerides < 100 mg/dL | Provides full lipid context; a downward HDL trend was hinted at in human data |
| Blood pressure | < 120/80 mmHg | Tracks the main potential benefit and guards against additive hypotension |
| Fasting glucose / HbA1c | Glucose 70–90 mg/dL; HbA1c < 5.4% | Screens for metabolic effects given mixed preclinical glucose findings |
| ALT & GGT (liver enzymes) | ALT < 25 U/L (men) / < 20 U/L (women); GGT low-normal | Liver enzymes both signal safety and were the markers improved by the combination product |
Cadence: Baseline, then 6–12 weeks after starting, then every 6–12 months with continued use; more frequent lipid checks if a rise is detected or cardiovascular risk is a concern.